Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBC.1.3.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XBC.1.3.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XBC.1.3.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XBC.1.3.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XBC.1.3.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
JN.11.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
JN.11.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
JN.11.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
JN.11.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-19646.7China
JN.11.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
JN.11.1NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
JN.11.1NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
JN.11.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
XDLORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
XDLECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
XDLNCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
XDLNCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
XDLNUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
XDLNYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
XDLNHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
XDLORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
JN.17ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
JN.17ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
JN.17NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
JN.17NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-19646.7China
JN.17NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
JN.17NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
JN.17NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
JN.17ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
AY.29.1 (Delta)ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
AY.29.1 (Delta)ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
AY.29.1 (Delta)NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-21977.3China
AY.29.1 (Delta)NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
AY.29.1 (Delta)NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
AY.29.1 (Delta)NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
AY.29.1 (Delta)NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
AY.29.1 (Delta)ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
AY.29.2 (Delta)ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
AY.29.2 (Delta)ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-3196.01Germany
AY.29.2 (Delta)NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-21977.3China
AY.29.2 (Delta)NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4856.9China
AY.29.2 (Delta)NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
AY.29.2 (Delta)NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
AY.29.2 (Delta)NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-893.215Hong Kong
AY.29.2 (Delta)ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BC.1ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BC.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BC.1NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BC.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4914.61China
BC.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used